Supplemental Table 1 from Genetic Variation in an Mirna-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer

Fang Xiong,Chen Wu,Jiang Chang,Dianke Yu,Binghe Xu,Peng Yuan,Kan Zhai,Jian Xu,Wen Tan,Dongxin Lin

DOI: https://doi.org/10.1158/0008-5472.22388229

2023-01-01

Abstract:Supplemental Table 1 from Genetic Variation in an miRNA-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer

What problem does this paper attempt to address?

Supplementary Table S1 from Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer

Yuning Liu,Qingzhe Wu,Bin Jiang,Tingting Hou,Chuanqiang Wu,Ming Wu,Hai Song

DOI: https://doi.org/10.1158/1541-7786.26144994

2024-01-01

Abstract:Supplementary Table S1. Sequences for sgRNA, shRNA or siRNA.
A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Jiali Xu,Zhiqiang Yin,Hong Shen,Wen Gao,Yingying Qian,Dong Pei,Lingxiang Liu,Yongqian Shu

DOI: https://doi.org/10.1371/journal.pone.0079135

IF: 3.7

2013-01-01

PLoS ONE

Abstract:Background: Recent evidence indicates that microRNAs (miRNAs) can function as tumor suppressors and oncogenes. Single nucleotide polymorphisms (SNPs) at miRNA genes can influence the maturation of miRNAs or miRNA-mediated transcriptional regulation. Our objective was to investigate the association of SNPs in deregulated miRNAs with clinical outcome in patients with non-small cell lung cancer (NSCLC) in a Chinese population.Methods: Deregulated miRNAs in NSCLC and their SNPs were identified through public databases. A single SNP, rs895819 in pre-miR-27a, was found suitable for selection. TaqMan assays were performed for genotyping and to assess the effect on the overall survival (OS) and chemotherapy response in 576 NSCLC patients.Results: Log-rank test and Cox regression analysis indicated that the G allele of rs895819 was associated with shorter survival and increased risk of death in NSCLC [dominant model: 22.0 vs. 46.0 months, P<0.001; adjusted hazard ratio (HR) = 1.71, 95% confidential interval (CI): 1.12-2.26]. Further stepwise regression analysis suggested that this SNP was an independently unfavorable factor for the prognosis of NSCLC and the effect remained significant in subgroup analysis stratified by clinical parameters and treatment status. Moreover, multivariate logistic regression analysis showed that the subjects with AG/GG genotypes of rs895819 had significantly decreased response rate to platinum-based chemotherapy compared to those with the AA genotype.Conclusion: Our results suggest that the pre-miR-27a rs895819 polymorphism may influence NSCLC patients' clinical outcome. Further large sample studies should be used to validate our findings.
Supplementary Tables 1-4, Figure 1 from Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response

Dong Liang,Larissa Meyer,David W. Chang,Jie Lin,Xia Pu,Yuanqing Ye,Jian Gu,Xifeng Wu,Karen Lu

DOI: https://doi.org/10.1158/0008-5472.22384392.v1

2023-01-01

Abstract:Supplementary Tables 1-4, Figure 1 from Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response
Ethnic Differences in Frequencies of Gene Polymorphisms in the MYCL1 Region and Modulation of Lung Cancer Patients' Survival.

Monica Spinola,F. Stefania Falvella,Antonella Galvan,Carmen Pignatiello,Vera P. Leoni,Ugo Pastorino,Rita Paroni,Shuqing Chen,Vidar Skaug,Aage Haugen,Tommaso A. Dragani

DOI: https://doi.org/10.1016/j.lungcan.2006.10.023

IF: 6.081

2007-01-01

Lung Cancer

Abstract:Linkage disequilibrium (LD) analysis to refine a region associated with lung cancer progression on chromosome 1p34 identified a 106kb LD block that includes MYCL1, TRIT1 (tRNA isopentenyltransferase 1) and MFSD2 (major facilitator superfamily domain-containing 2). Case-only association study on SNPs mapping in TRIT1 and MFSD2 indicated that the rare Leu allele (frequency: 0.04) of the TRIT1 Phe202Leu variation predicts short survival as compared to the common Phe/Phe genotype (hazard ratio (HR)=1.7; 95% CI, 1.03–2.86; P=0.039) in 335 Italian lung adenocarcinoma samples. A replication study in an independent population of 246 Norwegian lung cancer patients confirmed the significant association of the Phe202Leu polymorphism with patients’ survival, but the rare allele was associated with better survival rate (HR=0.5; 95% CI, 0.26–0.91; P=0.023). The rare allele of TRIT1 Phe202Leu SNP was ∼seven-fold more frequent in Asian than in Caucasian subjects and three additional SNPs in the TRIT1 and MFSD2 genes showed ethnic differences in allelic frequencies. These results suggest that polymorphisms in the MYCL1 LD region affect lung cancer survival but that the functional element(s) may show population-specific patterns.
Analysis of Genetic Variants and the Cerna Network of Mir-9 in Non-Small Cell Lung Cancer

Shuangshuang Wu,Jiali Xu,Mingjiong Zhang,Xiao Lu,Kai Wang,Sibo Sun,Yu Wang,Jianqing Wu

DOI: https://doi.org/10.1089/dna.2021.0549

2022-01-01

DNA and Cell Biology

Abstract:Objective: To explore the role of single-nucleotide polymorphisms (SNPs) in hsa-miR-9 in non-small cell lung cancer (NSCLC). Methods: Log-rank and Cox regression analyses were conducted to assess the association of four functional SNPs of miR-9 with overall survival (OS) of Chinese patients with NSCLC. A reporter luciferase assay was performed to examine the relationship between the SNPs and transcriptional activity of miR-9. The expression of miR-9 in cells was detected by quantitative real-time PCR assay. Xenograft model was established in nude mice, which were treated with Lv-MiR-9-mimics or Lv-miR-9-inhibitor. A long noncoding RNA (lncRNA)-miR-9-messenger RNA (mRNA) competing endogenous RNA (ceRNA) network was established based on bioinformatics analyses. Results: We found that rs1501672 was associated with the prognosis of 1001 Chinese NSCLC patients (A>G, additive model: adjusted hazard ratio = 0.89, 95% confidence interval = 0.79-1.00, p = 0.056). Luciferase reporter assay showed higher luciferase activity with wild A allele than that with mutant G allele in 293T, SPC-A1, and A549 cell lines. The miR-9 level was significantly higher in lung cancer cells than normal lung cells. miR-9 was also over expressed in lung cancer tissue according to The Cancer Genome Atlas and gene expression omnibus databases. Xenograft models based on H1299 cells showed that lv-miR-9-inhibitor significantly decreased tumor growth compared with the lv-miR-9-NC group (p<0.001). Bioinformatics analysis showed that one target gene leukemia inhibitory factor receptor and two lncRNAs (KIAA0087 and GVINP1) were associated with OS of NSCLC patients. Conclusion: The rs1501672 of miR-9 was associated with the prognosis of NSCLC patients in the Chinese population. The lncRNA-miR-9-mRNA ceRNA network revealed potential molecular biological regulation pathways and prognostic biomarkers for NSCLC.
Genetic Variation in a Microrna-502 Minding Site in SET8 Gene Confers Clinical Outcome of Non-Small Cell Lung Cancer in a Chinese Population.

Jiali Xu,Zhiqiang Yin,Wen Gao,Lingxiang Liu,Yongmei Yin,Ping Liu,Yongqian Shu

DOI: https://doi.org/10.1371/journal.pone.0077024

IF: 3.7

2013-01-01

PLoS ONE

Abstract:BACKGROUND:Genetic variants may influence microRNA-target interaction through modulate their binding affinity, creating or destroying miRNA-binding sites. SET8, a member of the SET domain-containing methyltransferase, has been implicated in a variety array of biological processes. METHODS:Using Taqman assay, we genotyped a polymorphism rs16917496 T>C within the miR-502 binding site in the 3'-untranslated region of the SET8 gene in 576 non-small cell lung cancer (NSCLC) patients. Functions of rs16917496 were investigated using luciferase activity assay and validated by immunostaining. RESULTS:Log-rank test and cox regression indicated that the CC genotype was associated with a longer survival and a reduced risk of death for NSCLC [58.0 vs. 41.0 months, P = 0.031; hazard ratio = 0.44, 95% confidential interval: 0.26-0.74]. Further stepwise regression analysis suggested rs16917496 was an independently favorable factor for prognosis and the protective effect more prominent in never smokers, patients without diabetes and patients who received chemotherapy. A significant interaction was observed between rs16917496 and smoking status in relation to NSCLC survival (P<0.001). Luciferase activity assay showed a lower expression level for C allele as compared with T allele, and the miR-502 had an effect on modulation of SET8 gene in vitro. The CC genotype was associated with reduced SET8 protein expression based on immunostaining of 192 NSCLC tissue sample (P = 0.007). Lower levels of SET8 were associated with a non-significantly longer survival (55.0 vs. 43.1 months). CONCLUSION:Our data suggested that the rs16917496 T>C located at miR-502 binding site contributes to NSCLC survival by altering SET8 expression through modulating miRNA-target interaction.
Supplementary Table 1-3 from MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non–Small Cell Lung Cancer Patients

Xia Pu,Jack A. Roth,Michelle A.T. Hildebrandt,Yuanqing Ye,Hua Wei,John D. Minna,Scott M. Lippman,Xifeng Wu

DOI: https://doi.org/10.1158/0008-5472.22399995.v1

2023-01-01

Abstract:Supplementary Table 1-3 PDF file - 162K, Supplementary tables 1 and 2 include effect of selected SNPs on overall survival or recurrence in early stage NSCLC patients; Supplementary table 3 includes all the SNPs selected in the analysis
Genetic Polymorphisms in the Precursor MicroRNA Flanking Region and Non-Small Cell Lung Cancer Survival.

Zhibin Hu,Yongqian Shu,Yijiang Chen,Jiaping Chen,Jing Dong,Yao Liu,Shiyang Pan,Lin Xu,Jing Xu,Yi Wang,Juncheng Dai,Hongxia Ma,Guangfu Jin,Hongbing Shen

DOI: https://doi.org/10.1164/rccm.201005-0717oc

IF: 24.7

2011-01-01

American Journal of Respiratory and Critical Care Medicine

Abstract:RATIONALE:Previously, we reported that common variants in precursor microRNA (pre-miRNA) sequences played a role in the prediction of non-small cell lung cancer (NSCLC) survival.OBJECTIVES:To assess whether variants in the pre-miRNA flanking region can influence the clinical behavior of NSCLC.METHODS:We conducted a two-stage study to examine the impact of a panel of 85 single-nucleotide polymorphisms on the overall survival of 923 patients with NSCLC (568 in the screening set and 355 in the validation set) in China.MEASUREMENTS AND MAIN RESULTS:Eleven single-nucleotide polymorphisms were primarily associated with NSCLC survival in the univariate analysis. However, in the validation set, only miR-30c-1 rs928508 was consistently an NSCLC survival predictor and the protective role of rs928508 AG/GG genotypes was more pronounced among early-stage (stage I/II) patients and patients treated with surgery. The area under the curve at Year 5 was significantly increased from 0.658 to 0.741 after adding the miR-30c-1 rs928508 risk score to the traditional clinical risk score (stage and surgery). Furthermore, in the genotype-phenotype correlation analysis, rs928508 AG/GG genotypes were associated with a significantly decreased expression of precursor and mature miR-30c (P = 0.009 and 0.011), but not with that of its primary miRNA. The expression of the host nuclear transcription factor Y gene was correlated with pri-mir-30c-1, but not with rs928508 genotypes, implicating the coregulation of the transcription of nuclear transcription factor Y and pri-mir-30c-1.CONCLUSIONS:Our data indicated, for the first time, that genetic polymorphisms in the pre-miRNA flanking region may be prognostic biomarkers of NSCLC, and rs928508 is such a potential candidate.
Supplementary Table S8 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515844.v1

2024-01-01

Abstract:Table S8. The potential functional role of rs3744797 by VannoPortal database.
Table S1 from Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Fuman Qiu,Lei Yang,Xiaoxuan Ling,Rongrong Yang,Xiaorong Yang,Lisha Zhang,Wenxiang Fang,Chenli Xie,Dongsheng Huang,Yifeng Zhou,Jiachun Lu

DOI: https://doi.org/10.1158/1078-0432.22461843

2023-01-01

Abstract:Table S1. All SNPs located in the mature miRNAs sequence.
Supplementary Table S5 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515853.v1

2024-01-01

Abstract:Table S5.Candidate genes and SNPs.
Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer

Nan Ding,A-Bin You,Hu Yang,Guo-Sheng Hu,Chun-Ping Lai,Wen Liu,Feng Ye

DOI: https://doi.org/10.1158/1078-0432.22658845.v1

2023-01-01

Abstract:Table S1: Cloning sequence or targeting sequence used in this article.
Supplementary Table S9 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515841

2024-01-01

Abstract:Table S9.The frequency data of rs3744797.
Supplementary Table S6 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515850

2024-01-01

Abstract:Table S6. Log-rank analysis in candidate SNPs.
Abstract A3: MicroRNA-related Polymorphisms Are Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients

Xia Pu,Charles Lu,David J. Stewart,Jian Gu,Michelle A.T. Hildebrandt,Jie Lin,Scott M. Lippman,Xifeng Wu

DOI: https://doi.org/10.1158/1940-6207.prev-09-a3

2010-01-01

Cancer Prevention Research

Abstract:Abstract MicroRNAs (miRNA) can function as oncogenes or tumor suppressors. In this study, to test the hypothesis that genetic variation within miRNA processing genes or miRNA binding sites on cancer-related genes may alter clinical outcomes in non-small cell cancer (NSCLC) patients, we genotyped 77 single nucleotide polymorphisms (SNPs) from eight miRNA processing genes and 163 SNPs from 133 predicted miRNA binding sites in 598 patients with early stage (stage I, IIA and IIB) NSCLC to determine the effect of these variations on progression risk and overall survival. We further conducted a subset analysis to exclude potential bias due to different treatment regimens. We identified 37 SNPs associated with overall survival. In the surgery-only patients, 22 SNPs modulated overall survival, including FZD4:rs713065 that remained significant for decreased risk after multiple comparisons (HR: 0.53, 95% CI: 0.36–0.77). For progression risk, 21 and 25 SNPs were found to be significant in the entire and surgery-only patient populations, respectively. Following multiple comparison, ICAM1:rs281437 (HR: 1.80, 95% CI: 1.29–2.52) and MDM4:rs10900596 (HR: 2.01, 95% CI: 1.26–3.19) remained significant increase in progression risk, while FAS:rs2234978 (HR: 0.58, 95% CI: 0.41–0.80) displayed a significantly protective effect. CDC7:rs12125947 (HR: 2.19, 95% CI: 1.37–3.51) remained significant risk effect in the surgery-only patients. A strong cumulative, dose-effect of these variant genotypes to increase risk and dramatically decrease median event-free time was consistently observed. We also identified potential higher-order gene-gene interactions among these SNPs. With validation, our result can be used in the prognosis of clinical outcomes for early stage NSCLC patients. Citation Information: Cancer Prev Res 2010;3(1 Suppl):A3.
Supplementary Table S4 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515856.v1

2024-01-01

Abstract:Table S4. The differentially expressed genes between gefitinib-sensitive and gefitinib-resistant NSCLC cells.
Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

Ling-Min Kong,Cheng-Gong Liao,Yang Zhang,Jing Xu,Yu Li,Wan Huang,Yi Zhang,Huijie Bian,Zhi-Nan Chen

DOI: https://doi.org/10.1158/0008-5472.22402862

2023-01-01

Abstract:PDF file - 75K, Oligonucleotide sequence of PCR primers and siRNA fragments.
Supplementary Table S1 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan,Xi Chen,Yuru Wei,Fei Wang,Wen Xie,Youhao Chen,Heng Liang,Xia Zhu,Yunpeng Yang,Wenfeng Fang,Yan Huang,Hongyun Zhao,Xiaoxu Zhang,Shu Liu,Wei Zhuang,Min Huang,Xueding Wang,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.25515865.v1

2024-01-01

Abstract:Table S1. Patients’ characteristics.
Supplementary Table 1 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Jianzhong Cao,Yongmei Song,Nan Bi,Jie Shen,Wenyang Liu,Jing Fan,Guogui Sun,Tong Tong,Jie He,Yuankai Shi,Xun Zhang,Ning Lu,Yinghua He,Hongyu Zhang,Kelong Ma,Xiaoying Luo,Lei Lv,Hui Deng,Jing Cheng,Jingde Zhu,Luhua Wang,Qimin Zhan

DOI: https://doi.org/10.1158/0008-5472.22397204

2023-01-01

Abstract:PDF file - 53K, The sequences for the four plasmids.
Supplementary Figures S1-S4 and Tables S1-S3 from A Rare Missense Variant in TCF7L2 Associates with Colorectal Cancer Risk by Interacting with a GWAS-Identified Regulatory Variant in the MYC Enhancer

Jiang Chang,Jianbo Tian,Yang,Rong Zhong,Jiaoyuan Li,Kan Zhai,Juntao Ke,Jiao Lou,Wei Chen,Beibei Zhu,Na Shen,Yi Zhang,Yajie Gong,Ying Zhu,Danyi Zou,Xiating Peng,Kun Huang,Xiaoping Miao

DOI: https://doi.org/10.1158/0008-5472.22426461

2023-01-01

Abstract:It contains the PCA plots (Figure S1), QQ plot (Figure S2), regional plots (Figure S2) and luciferase reporter assay results for rs11169571 with hsa-mir-524-5p (Figure S4). It also contains the characteristic of study subjects (Table S1) and results of discovery (Table S3) and replication stages (Table S3).

Supplemental Table 1 from Genetic Variation in an Mirna-1827 Binding Site in MYCL1 Alters Susceptibility to Small-Cell Lung Cancer

Supplementary Table S1 from Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung Cancer

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Supplementary Tables 1-4, Figure 1 from Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response

Ethnic Differences in Frequencies of Gene Polymorphisms in the MYCL1 Region and Modulation of Lung Cancer Patients' Survival.

Analysis of Genetic Variants and the Cerna Network of Mir-9 in Non-Small Cell Lung Cancer

Genetic Variation in a Microrna-502 Minding Site in SET8 Gene Confers Clinical Outcome of Non-Small Cell Lung Cancer in a Chinese Population.

Supplementary Table 1-3 from MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non–Small Cell Lung Cancer Patients

Genetic Polymorphisms in the Precursor MicroRNA Flanking Region and Non-Small Cell Lung Cancer Survival.

Supplementary Table S8 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Table S1 from Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Supplementary Table S5 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S1 from A Tumor-suppressive Molecular Axis EP300/circRERE/miR-6837-3p/MAVS Activates Type I IFN Pathway and Antitumor Immunity to Suppress Colorectal Cancer

Supplementary Table S9 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S6 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Abstract A3: MicroRNA-related Polymorphisms Are Associated with Clinical Outcomes in Early Stage Non-Small Cell Lung Cancer Patients

Supplementary Table S4 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

Supplementary Table S1 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table 1 from DNA Methylation-Mediated Repression of miR-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Figures S1-S4 and Tables S1-S3 from A Rare Missense Variant in TCF7L2 Associates with Colorectal Cancer Risk by Interacting with a GWAS-Identified Regulatory Variant in the MYC Enhancer